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Propionyl CoA carboxylase (PCC) is a mitochondrial, biotin-dependent enzyme involved in the catabolism of amino
acids, odd-chain fatty acids, and other metabolites. PCC consists of two subunits, a and b, encoded by the PCCA
and PCCB genes, respectively. Inherited PCC deficiency due to mutations in either gene results in propionic acidemia
(PA), an autosomal recessive disease. Surprisingly, PA is highly prevalent among Inuits in Greenland. We have
analyzed reverse transcriptase–PCR products of the b-subunit mRNA, to characterize the responsible mutation(s).
A 3-bp insertion, 1540insCCC, was found in homozygous form in three patients and in compound heterozygous
form in one patient. The resulting PCC has no measurable activity, and the mutant b-subunit appears to be very
unstable. To test the hypothesis that a common mutation is responsible for PA in the Greenlandic Inuit population,
310 anonymous DNA samples of Inuit origin were screened for 1540insCCC. We found a carrier frequency of
5%, which is very high compared with those of most other autosomal recessive diseases. Analysis of alleles of a
very closely linked marker, D3S2453, revealed a high degree of linkage disequilibrium between one specific allele
and 1540insCCC, suggesting that this mutation may be a founder mutation.
Propionic acidemia (PA [MIM 232000 and 232050]) is
an autosomal recessive disorder caused by a deficiency
of propionyl CoA carboxylase (PCC [E.C.6.4.1.3]). PCC
is a biotin-dependent mitochondrial enzyme involved in
the catabolism of odd-chain fatty acids and of the amino
acids threonine, methionine, isoleucine, and valine. PCC
consists of two nonidentical subunits, a and b, encoded
by the PCCA and PCCB genes, respectively. The native
enzyme is believed to have an a6b6 conformation (Fen-
ton and Rosenberg 1995). The subunits are synthesized
as larger precursors, imported into mitochondria, pro-
cessed to mature forms, and assembled (Kraus et al.
1983). Both human aPCC cDNA and human bPCC
cDNA have been cloned, and their loci have been
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mapped (Kraus et al. 1986; Lamhonwah et al. 1986).
Patients with a defect in either PCCA or PCCB present
early in life, with a severe, often fatal, metabolic acidosis,
hyperglycinemia, and hyperammonemia. Survivors are
prone to recurrent attacks of acidemia. Unusual forms
with a later onset have been reported for both genes
(Fenton and Rosenberg 1995). Recently, 53 mutations
in both genes have been reviewed (Ugarte et al. 1999;
for up-to-date information, see the Propionyl CoA Car-
boxylase Page Web site).
The worldwide frequency of PA is unknown, but the
disease is considered to be very rare. Our department
diagnosed five patients with PA who are of Greenlandic
Inuit origin, within the period 1990–96 (the project was
conducted in agreement with Helsinki declaration II and
was approved by the Science Ethics Committee for Co-
penhagen and Frederiksberg). This number of patients
is much higher than expected, considering the size and
the birth rate of the Greenlandic population. The most
obvious explanation for this observation is the presence
of one common mutation among Inuits in Greenland.
204 Am. J. Hum. Genet. 67:203–206, 2000
Table 1
PCC Activity in Skin Fibroblasts of Patients and in E. coli
Source
PCC Specific Activitya
(nmol/min/mg protein) PCC Genotypea
Fibroblasts:
Controls .42–2.6b Wild type/wild type
Patient 1 .04 1540insCCC/unknown
Patient 2 NA NAc
Patient 3 !.02 1540insCCC/1540insCCC
Patient 4 NA NA
Patient 5 !.02 1540insCCC/1540insCCC
Patient 6 !.02 1540insCCC/1540insCCC
E. coli:
Wild type 30 Wild type
513insP 0 1540insCCC
NOTE.—NA = not available.
a Assayed by measurement of the fixation of [14C]-HCO3
 into acid-
soluble material (Kalousek et al. 1980). Protein concentration was
determined by Bio-Rad assay kit.
b Mean activity of control cell lines.
c The mother was heterozygous for 1540insCCC.
Figure 1 Western blot analysis of PCC a- and b-subunits. A,a-
and b-subunits expressed in fibroblasts. Lane 1, Purified recombinant
human PCC (100 ng). Lane 2, Control fibroblast cell line 2047 (80
mg). Lane 3, Cell line 3173, from the patient homozygous for
1540insCCC (80 mg). B, a- and b-subunits expressed in E. coli. Lane
1, Purified recombinant human PCC (100 ng). Lanes 2 and 3, Equal
amounts of crude bacterial extracts (30 mg), expressing either wild-
type PCC (lane 2) or 1540insCCC (513insP) (lane 3) protein. Lane 4,
Bacterial extract from DH5a cells without pPCCAB plasmid (30 mg).
The family histories of our probands were highly sug-
gestive of previous siblings with PA. The current pop-
ulation size of Greenland is 55,000, of which 50,000
are of Inuit origin, and the birth rate is ∼1,000/year.
There was no indication of consanguinity among the
families, and the birthplaces of the patients were widely
scattered over Greenland. Given the birth ratementioned
above, a rough first estimate of the disease frequency at
birth is 1:1,000, with a carrier frequency of 1:16.
Assuming that one mutation is responsible for PA
among Inuits in Greenland, we used a single patient
(patient 6) for our initial investigations. The patient had
very low to undetectable activity; however, the activities
found in parental fibroblasts were in the normal range.
These results suggested a defect in the b-subunit of PCC
(Fenton and Rosenberg 1995), and the search for mu-
tations was first directed at PCCB. Amplification of
overlapping segments of the bPCC cDNA, followed by
SSCP, revealed a PCR product with an aberrant pattern.
Reamplification of this segment, followed by direct se-
quencing, identified a homozygous insertion of CCC at
nucleotide 1540 (1540insCCC) (results not shown). This
mutation predicts an insertion of a proline residue be-
tween positions 513 and 514 in the b-subunit (513insP),
without disturbance of the reading frame of the mRNA.
As expected, both parents were heterozygous for
1540insCCC. Detection of 1540insCCC was performed
with the following primers: 5′-FITC-CCTTTTCTGT-
GCTTCACCAG-3′ forward) and 5′-ACCTTCTTGCT-
GGCCAAGA-3′ (reverse). The sizes of the normal and
mutant alleles were 103 and 106 bp, respectively. The
PCR products were analyzed by an ALF-sequenatorwith
Fragment Manager software (Pharmacia).
We had access to cell lines from two other patients
and to one chorionic villus sample from a PCC-deficient
fetus, from the total of six families affected by PA. Two
of the samples showed homozygosity for 1540insCCC,
and the other sample was compound heterozygous for
1540insCCC and another, yet-unidentified mutation (ta-
ble 1).
To analyze the PCC polypeptides under steady-state
conditions in fibroblasts of the patient homozygous for
the 1540insCCC (patient 6, cell line 3173), we per-
formed western blot analysis with rabbit anti-human
PCC antiserum. Figure 1A shows that the levels of the
a-subunit in both cell lines were comparable; however,
the b-subunit was not detectable in the patient’s fibro-
blasts. In contrast to the mutations in the a-subunit,
which secondarily lead to the complete degradation of
the b-subunit, mutations in the b-subunit were found to
yield either decreased amounts or a smaller size of the
subunit (Lam Hon Wah et al. 1983; Ohura et al. 1989,
1991; Rodriguez-Pombo et al. 1998).
To partially characterize the mutant PCC protein, the
1540insCCC was introduced into a pPCCAB plasmid
and was expressed in Escherichia coli. The construction
of pPCCAB plasmid containing both aPCC cDNA and
bPCC cDNA has been described elsewhere (Kelson et al.
1996). The pPCCAB/1540insCCC vector was prepared
by insertion of a double-stranded hybrid of two oligonu-
cleotides (82-mer and 86-mer) into pPCCAB cut at
unique Pst I andMsc I sites within exon 15 of the PCCB.
After DNA sequencing, DH5a cells were transformed
with the construct. PCC activity in E. coli extracts was
assayed as described elsewhere (Kalousek et al. 1980),
with the slight modification of changing the pH of Tris-
HCl from 8.0 to 7.0. Protein was determined by the
method of Lowry (Lowry et al. 1951).
Bacterial extracts showed no detectable activity of the
mutant PCC (table 1). In addition, western blot analysis
of these extracts has shown that the mutation, similar
to the situation in fibroblasts, leads to degradation of
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Table 2








of Base Pairs) Frequency Genotype
No. Expecteda/
No. Found
1 (320) .24 1-1 1/5
2 (324) .51 1-2 4.65/8
3 (328) .16 1-3 1.45/4
4 (332) .09 1-4 .82/4
2-2 4.94/4
Other 6.13/0
a Calculated on the basis of frequencies found in controls, given
linkage equilibrium between 1540insCCC and D3S2453.
the b-subunit (fig. 1B). This result might indicate that
bacteria do not tolerate unassembled bPCC subunits and
degrade them intracellularly.
The mutation is in exon 15, the last exon of the b-
subunit. Exon 15, together with exon 12, are the sites
where approximately half of the PCCB mutations have
been identified in patients affected by PA (Ugarte et al.
1999). Moreover, on the basis of results of computer
analysis, the segment encoded by exon 15 may be ex-
posed to the surface of the oligomeric structure (data
not shown). The introduction of one proline—a strong
a-helix and b-sheet breaker—into this region may
change the overall conformation of the PCC protein.
Taken together, our results indicate that this mutation
is clearly a disease-causing mutation rather than a benign
variant. This is only the second mutation that has been
confirmed, by expression in bacteria, to be pathogenic
(Kelson et al. 1996).
At the time of the identification of 1540insCCC, the
genomic structure of PCCB also was published (Rod-
riguez-Pombo et al. 1998). Using this information, we
were able to design primers flanking the site of
1540insCCC, for direct amplification of genomic DNA,
thereby allowing a simple population screening for the
mutation. Testing two sets of data—200 anonymous,
randomly chosen Guthrie (phenylketonuria) cards on
children of Inuit origin who had been born in Greenland
and 110 anonymous blood samples of Inuit origin that
had been taken for other purposes—we identified 8 het-
erozygous individuals among the 200 Guthrie cards and
7 heterozygous individuals among the other 110 blood
samples. The carrier frequencies were 4% and 6%, re-
spectively ( ), of a total carrier frequency of 15/P = .2
310, or 5% (95% confidence interval 1.9%–7.7%). The
mutation was not found in 50 samples from Denmark.
Although the Inuits from whom the 110 blood samples
were obtained lived in the same part of Greenland and
therefore might be related, the 200 blood-spot samples
were randomly chosen and therefore are expected to be
representative of the Greenlandic Inuit population as a
whole; however, there was no statistical difference be-
tween the carrier frequencies in the two groups. Fur-
thermore, the combined carrier frequency of ∼5% was
very close to the carrier frequency calculated on the basis
of the number of patients observed as affected by PA.
To support the hypothesis of an ancestral mutation,
we determined the allele frequencies of the tetranucle-
otide repeat STR D3S2453, which has been mapped to
the same YAC (971_c_7) as PCCB (Piemontese et al.
1997), using the primers 5′-FITC-AATTACTTGCACT-
GGCATCC-3′ and 5′-GAGAGGGAGAAAGAAATGT-
GC-3′ (Genome Database accession number 685179).
The fragments were analyzed as described for the de-
tection of the 1540insCCC mutation. The allele fre-
quencies of D3S2453 among 50 individuals without
1540insCCC, as well as the genotypes of the 4 patients
and 15 persons heterozygous for 1540insCCC, are
shown intable 2. We found four different alleles of
D3S2453 in the control Inuit population. The patients
homozygous for 1540insCCC were all homozygous for
an allele of 320 bp (allele 1), and 14 of the 15 persons
heterozygous for 1540insCCC had in common at least
one copy of allele 1. Using the allele frequencies found
in the 50 controls, we calculated, given linkage equi-
librium, the expected genotypes for the individuals ho-
mozygous or heterozygous for 1540insCCC. We found
evidence of strong linkage disequilibrium between allele
1 and 1540insCCC ( ; , df 5). This2P K .001 x = 32.5
finding may indicate that the high frequency of
1540insCCC among Inuits is due to a common ancestor.
Unfortunately, we had no access to family members of
the patients and were unable to do extended haplotype
analyses. An attempt to support the hypothesis, using
another polymorphic marker (D3S3528 [Genome Da-
tabase accession number 598974]) located on the same
YAC but on the other site of PCCB, was unsuccessful,
since the Inuit population was uninformative for this
marker.
The present Inuit population is believed to have de-
scended from Eskimos who settled in Greenland circa
year 1200 of the common era, and mtDNA analyses
have demonstrated a close relationship between the
Greenlandic Inuits and the circumarctic North American
Eskimos (Forster et al. 1996; J. Saillard, P. Forster, N.
Lynnerup, H.-J. Bandelt, and S. Nørby, personal com-
munication). It is likely that PA is responsible for some
of the neonatal morbidity and mortality in the latter
population.
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